期刊
CANCER
卷 116, 期 11, 页码 2758-2759出版社
WILEY-BLACKWELL
DOI: 10.1002/cncr.25171
关键词
inflammatory breast cancer; vasculolymphatic processes; epidermal growth factor receptor; erlotinib; extracellular signal-regulated protein kinase
类别
资金
- NATIONAL CANCER INSTITUTE [R01CA123318] Funding Source: NIH RePORTER
- NCI NIH HHS [R01CA123318-01A1] Funding Source: Medline
Despite the introduction of multimodality treatment approaches, the prognosis of inflammatory breast cancer (IBC) is poor. Recent developments in molecular targeted therapy may be effective against IBC. The authors report the results of a literature review. Trastuzumab and lapatinib, which target human epidermal growth factor receptor 2 (HER-2), have demonstrated benefit in clinical trials for HER-2-positive breast cancers. WNT1-inducible signaling pathway protein 3, Ras homolog gene family member C guanosine triphosphatase, epidermal growth factor receptor (EGFR), and p27(kip1) also have been studied as potential targets in IBC. Molecular targets in vasculolymphatic processes (angiogenesis, lymphangiogenesis, and vasculogenesis) have demonstrated greater potential in IBC than in non-IBC. Although loss of E-cadherin is a hallmark of epithelial-to-mesenchymal transition and may correlate with the promotion of metastasis, paradoxically, E-cadherin is overexpressed in IBC through an unknown mechanism. On the basis of dissecting the molecular mechanism of the aggressiveness of IBC, the authors currently are-investigating whether EGFR may aid in developing innovative targeted therapies. Cancer 2010;116(11 suppl):2758-6. (C) 2070 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据